Not the question you asked but the Chinese company Sinopharm has started phase 3 trials of a classic inactivated virus vaccine (and Bharat Biotech is starting phase 2 trials as well in India). The difficulty will be mass-producing it, of course, but we aren't necessarily reliant on novel vaccine technologies.